Even with Israel’s world-leading rollout of Covid-19 vaccinations,
drugs to treat Covid patients are in desperate need across the world.
Two such drugs developed in Israel show great promise in clinical
trials: EXO-CD24 and Allocetra.
EXO-CD24, an experimental inhaled medication developed at Tel Aviv
Sourasky Medical Center, cured all 30 moderate-to-severe cases in a
Phase I clinical trial.
Developed over the past six months at the hospital, EXOCD24 stops the
“cytokine storm” – where the immune system goes out of control and
starts attacking healthy cells – that occurs in the lungs of 5-7% of
“To date, the preparation has been tried with great success on 30
severe patients, in 29 of whom the medical condition improved within
two to three days and most of them were discharged home within three to
five days. The 30th patient also recovered but after a longer time,”
the hospital reports.
“The drug is based on exosomes, [vesicles] that are released from the
cell membrane and used for intercellular communication. We enrich the
exosomes with 24CD protein. This protein is expressed on the surface of
the cell and has a known and important role in regulating the immune
system,” explained Dr. Shiran Shapira, director of the laboratory of
Prof. Nadir Arber, who has been researching the CD24 protein for over
“The preparation is given by inhalation, once a day, for only a few
minutes, for five days,” Shapira said.
She said the experimental treatment has two unique characteristics. The
first is that it inhibits the over-secretion of cytokines. The second
is that it is delivered directly to the lungs and therefore has no
systemic side effects that injected or oral drugs can cause.
“Even if the vaccines perform their function, and even if no new
mutations are produced then still in one way or another the corona will
remain with us,” said Arber, director of the medical center’s
Integrated Cancer Prevention Center. “To this end, we have developed a
unique drug, EXO-CD24.”
Arber added that this advanced preparation “can be produced quickly and efficiently and at a very low cost in every pharmaceutical facility in
the country, and in a short time globally.”
Prof. Ronni Gamzu, CEO of the medical center, said, “Prof. Arber’s
results for first-phase research were excellent and gave us all
confidence in the method he has been researching [here] for many years.
I personally assisted him in further obtaining the approvals from the
Ministry of Health for further research.”
Meanwhile, Enlivex Therapeutics last week reported positive results
from a multi-center Phase II clinical trial of its experimental Covid-
19 immunotherapy drug Allocetra in severe and critical Covid-19
We reported in October that five Covid-19 intensive care patients were discharged from Hadassah University Medical Center in Jerusalem after
Nine severe and seven critical Covid-19 patients were treated with
Allocetra in the Phase II clinical trial. Fourteen of them recovered
and were discharged from the hospital after an average of 5.3 days.
The Phase II trial originally was expected to enroll 24 patients but
was “completed early in support of anticipated accelerated regulatory
filings of the trial’s positive safety and efficacy data,” Enlivex
Altogether, 19 out of 21 Phase II and Phase Ib Allocetra trial patients recovered and were discharged from the hospital after an average of 5.6
days. Most of the patients in both studies had pre-existing risk
factors such as male gender, obesity and hypertension.
“The results we have seen from the 12 Covid-19 patients treated to date
with Allocetra are exciting,” said Prof. Vernon van Heerden, head of
the General Intensive Care Unit at Hadassah and the lead investigator
of both clinical trials.
“The Phase II patients who have been discharged from the hospital are
currently healthy. We believe that these compelling results have
demonstrated the safety and efficacy of Allocetra in these complicated patients, highlighting the potential of Enlivex’s product candidate to
benefit severe and critical Covid-19 patients as well as others
suffering from cytokine storms and organ dysfunctions across various
Allocetra is based on the research of Enlivex chief scientific and
medical officer Dr. Dror Mevorach, head of internal medicine and of one
of Hadassah’s coronavirus wards. It works by restoring balance to the
Mevorach said Allocetra “may have utility as a safe and efficacious
treatment … regardless of the specific coronavirus mutation that
afflicted the patients, and across different life-threatening, high
mortality clinical indications with high unmet medical needs.”
For over 16 years, ISRAEL21c has brought you the faces and places of
Israel every day, spreading the word about Israel to millions of people
in virtually every country around the globe. First of its kind, our
content is originally researched, written and produced by seasoned
experts directly from Israel.
We cannot do this without financial support from people like you.
Become a GEM member and enjoy exclusive briefings from our staff and
more - for $18 a month.